Entera Bio Ltd. (ENTX)

Market Cap	33.42M
Revenue (ttm)	134,000
Net Income (ttm)	-13.07M
Shares Out	28.81M
EPS (ttm)	-0.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	66,039
Open	1.17
Previous Close	1.22
Day's Range	1.11 - 1.23
52-Week Range	0.47 - 3.00
Beta	1.80
Analysts	Buy
Price Target	5.78 (+398.28%)
Earnings Date	May 10, 2023

About ENTX

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreeme...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 28, 2018
• Employees: 19
• Stock Exchange: NASDAQ
• Ticker Symbol: ENTX

Financial Performance

In 2022, Entera Bio's revenue was $134,000, a decrease of -76.53% compared to the previous year's $571,000. Losses were -$13.07 million, 7.25% more than in 2021.

Analyst Forecast

According to 9 analysts, the average rating for ENTX stock is "Buy." The 12-month stock price forecast is $5.78, which is an increase of 398.28% from the latest price.

Price Target

$5.78

(398.28% upside)

Analyst Consensus: Buy